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Reported	directly	to	Silvia	Resta-Lenert,	M.D.,	Ph.D.,	Assistant	Professor	in	the	lab	of	Kim	Barrett,	Ph.D..	
Main	project	focused	on	the	role	of	synbiotics	(prebiotics	+	probiotics)	and	the	upregulation	of	the	MCT1	
transporter	protein	(a	transporter	of	butyrate).	Performed	western	blots,	immunoprecipitation,	solution	
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